1. Novo Nordisk has filed an emergency legal motion aiming to stop Eli Lilly from running advertisements on its weight-loss medications. The complaint focuses on Eli Lilly’s ads making misleading comparisons with Novo Nordisk’s flagship drugs, Wegovy and Ozempic.
The court request highlights concerns that these ads may confuse patients and healthcare providers by exaggerating the effectiveness or safety of Eli Lilly’s products relative to Novo Nordisk’s established treatments. Such claims can impact market competition and patient choices amid the booming demand for weight-loss therapies.
